ASLAN Pharmaceuticals Limited (ASLN)
| Market Cap | 226.26M |
| Revenue (ttm) | 189,710 |
| Net Income (ttm) | -22.07M |
| Shares Out | 69.62M |
| EPS (ttm) | -0.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,135,594 |
| Open | 3.26 |
| Previous Close | 3.24 |
| Day's Range | 3.12 - 3.36 |
| 52-Week Range | 1.42 - 6.75 |
| Beta | 2.37 |
| Analysts | Buy |
| Price Target | 5.50 (+69.2%) |
| Est. Earnings Date | Nov 5, 2021 |
About ASLN
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for mark...
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for ASLN stock is "Buy." The 12-month stock price forecast is 5.50, which is an increase of 69.23% from the latest price.
News
ASLAN Pharmaceuticals to Participate in the 2021 Cantor Virtual Global Healthcare Conference
MENLO PARK, Calif., and SINGAPORE, Sept. 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments...
ASLAN Pharmaceuticals Establishes Scientific Advisory Board Chaired by Distinguished Dermatology Expert Dr Lawrence E...
MENLO PARK. Calif. and SINGAPORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments...
Implied Volatility Surging for ASLAN Pharmaceuticals (ASLN) Stock Options
Investors need to pay close attention to ASLAN Pharmaceuticals (ASLN) stock based on the movements in the options market lately.
ASLAN Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
SINGAPORE, Aug. 06, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives ...
ASLAN Pharma Secures Debt Funding Of $45M To Support ASLAN003 Development
ASLAN Pharmaceuticals (NASDAQ: ASLN) has closed a secured loan facility provided by K2 HealthVentures (K2HV). Under the terms of the facility, K2HV will provide ASLAN up to $45 million of secured debt ...
ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 Million From K2 HealthVentures
Funds extend expected cash runway through late 2023 and enable advancement of clinical program for ASLAN003 Funds extend expected cash runway through late 2023 and enable advancement of clinical program...
Why ASLAN Pharmaceuticals Blasted Higher on Friday
An analyst initiates the company's stock with a very bullish note.
New Strong Sell Stocks for June 8th
ASLN, CANG, ESLT, GCI, and KRYS have been added to the Zacks Rank #5 (Strong Sell) List on June 8, 2021.
New Strong Sell Stocks for June 4th
ASLN, BLRX, FLXN, ICMB, and MRNS have been added to the Zacks Rank #5 (Strong Sell) List on June 4, 2021.
ASLAN Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
- Next data readout for ASLAN004 in the treatment of patients with moderate to severe atopic dermatitis anticipated in the third quarter of 2021 - Phase 2b clinical trial for ASLAN004 expected to initi...
ASLAN Pharmaceuticals to Present Data on ASLAN004 at Society for Investigative Dermatology
- ASLAN will give a poster presentation of new data from its Single Ascending Dose (SAD) study of ASLAN004, during the virtual event on 6 May, 2021
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Next data readout for ASLAN004 in the treatment of patients with moderate to severe atopic dermatitis anticipated in the third quarter of 2021 Next data readout for ASLAN004 in the treatment of patients...
What Makes ASLAN Pharmaceuticals Ltd. (ASLN) a New Buy Stock
ASLAN Pharmaceuticals Ltd. (ASLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ASLAN Pharmaceuticals Announces Pricing of Public Offering of American Depositary Shares
SINGAPORE, March 03, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives ...
ASLAN Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
SINGAPORE, March 01, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives ...
ASLN Stock: Why Aslan Pharmaceuticals Is Up 20% Today
Investors in ASLN stock seem to like the company's initial clinical test results, as well as the company's overall market position. The post ASLN Stock: Why Aslan Pharmaceuticals Is Up 20% Today appeare...
Aslan Pharmaceuticals Shares Are Trading Higher On Positive ASLAN004 Data In Atopic Dermatitis
Aslan Pharmaceuticals Ltd (NASDAQ: ASLN) announces positive interim unblinded data from its ongoing Phase 1 study evaluating ASLAN004 to treat moderate to severe atopic dermatitis (AD). Subcutaneous del...
ASLAN Pharmaceuticals Announces Positive Interim Data From the Multiple Ascending Dose Study of ASLAN004 in Atopic De...
- 74% average reduction in EASI from baseline at therapeutic doses after 8 weeks. 89% of patients achieved EASI-50 and 56% achieved EASI-90
ASLAN Pharmaceuticals Announces $18 Million Private Placement
SINGAPORE, Feb. 25, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of...
ASLAN Pharmaceuticals Appoints Dr Neil Graham as Independent Director
SINGAPORE, Feb. 18, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of...
New Research Published in Toxicology in Vitro Provides Insight Into the Hepatotoxicity of DHODH Inhibitors Suggesting...
— New research shows ASLAN003 to have the lowest potential for hepatotoxicity of the compounds tested despite being one of the most potent DHODH inhibitors
ASLAN Pharmaceuticals Opens Expansion Cohort in ASLAN004 Atopic Dermatitis Clinical Trial
- ASLAN has completed recruitment of patients into the third, highest dose cohort of ASLAN004 in AD patients. ASLAN004 was found to be well tolerated at all dose levels
ASLAN Pharmaceuticals Ltd. (ASLN) Moves to Buy: Rationale Behind the Upgrade
ASLAN Pharmaceuticals Ltd. (ASLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference
SINGAPORE, Nov. 19, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of...
ASLAN Pharmaceuticals (ASLN) Sees Hammer Chart Pattern: Time to Buy?
ASLAN Pharmaceuticals (ASLN) has been struggling lately, but the selling pressure may be coming to an end soon.